---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030996"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:25:43.546875+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics reports Q2 net income $5.2M but warns of going concern doubt

## Summary
- Net income $5.2M ($0.61 basic EPS) includes $9.3M non-cash warrant revaluation; operating loss $3.8M.
- Cash and restricted cash $6.1M at June 30; $11.2M owed to Juvenescence; substantial doubt about continuing as going concern.
- Research and development expenses $1.6M (+$1.1M YoY); G&A $2.3M (+$1.8M YoY) partly from Merger costs.
- Partnered with Enable Injections to develop SER-252 (POZ-apomorphine) for Parkinson's; IND planned for 2025.
- Appointed Dr. Srini Tenjarla as SVP of CMC & Formulation; presented POZ-lipid immunogenicity data.

## SEC filing metadata
- accession: 0001493152-24-030996
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315224030996/0001493152-24-030996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315224030996/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030996
- JSON: https://secwatch.observer/filing/0001493152-24-030996.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030996.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.